The spread of antimicrobial resistance continues to be a priority health concern worldwide, necessitating the exploration of alternative therapies. Cannabis sativa has long been known to contain antibacterial cannabinoids, but their potential to address antibiotic resistance has only been superficially investigated. Here, we show that cannabinoids exhibit antibacterial activity against methicillin-resistant Staphylococcus aureus (MRSA), inhibit its ability to form biofilms, and eradicate preformed biofilms and stationary phase cells persistent to antibiotics. We show that the mechanism of action of cannabigerol is through targeting the cytoplasmic membrane of Gram-positive bacteria and demonstrate in vivo efficacy of cannabigerol in a murine systemic infection model caused by MRSA. We also show that cannabinoids are effective against Gram-negative organisms whose outer membrane is permeabilized, where cannabigerol acts on the inner membrane. Finally, we demonstrate that cannabinoids work in combination with polymyxin B against multidrug resistant Gram-negative pathogens, revealing the broad-spectrum therapeutic potential for cannabinoids.

中文翻译：

---

发掘大麻的隐藏抗生素潜力。

抗菌素耐药性的传播仍然是世界范围内对健康的优先考虑，因此有必要探索替代疗法。早就知道大麻中含有抗菌大麻素，但其解决抗生素耐药性的潜力只是表面研究。在这里，我们显示大麻素对耐甲氧西林的金黄色葡萄球菌（MRSA）表现出抗菌活性，抑制其形成生物膜的能力，并根除对抗生素具有持久性的预先形成的生物膜和固定相细胞。我们表明，大麻酚的作用机理是通过靶向革兰氏阳性细菌的细胞质膜，并证明大麻酚在由MRSA引起的小鼠全身感染模型中的体内功效。我们还显示，大麻素可有效对抗革兰氏阴性生物，其外膜被透化，其中大麻二酚作用于内膜。最后，我们证明了大麻素与多粘菌素B共同对抗多重耐药性革兰氏阴性病原体，揭示了大麻素的广谱治疗潜力。